GI Insights CME
This CME series focuses on improving the overall management of patients with GI disease. Faculty experts provide education that is designed to strengthen clinician skill-sets needed to provide not only better patient care —via enhanced diagnosis and management strategies—but also to optimize patient outcomes through strategies that are meant to improve therapeutic adherence.
Episodes 1-12 of 12
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
MinuteCE®What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
MinuteCE®How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
MinuteCE®Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
MinuteCE®HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
MinuteCE®Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
MinuteCE®Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
MinuteCE®Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
MinuteCE®What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
MinuteCE®Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
MinuteCE®Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
MinuteCE®What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
